{
  "critical_care_questions": [
    {
      "category": "vasopressor_pharmacology",
      "questions": [
        "What are the pharmacokinetic parameters of vasopressors in septic shock?",
        "How do alpha-adrenergic agonists affect systemic vascular resistance?",
        "What are the monitoring parameters for norepinephrine therapy?",
        "How does vasopressin differ from catecholamine vasopressors?",
        "What are the contraindications for high-dose epinephrine?"
      ]
    },
    {
      "category": "hemodynamic_monitoring", 
      "questions": [
        "What are the hemodynamic targets in distributive shock?",
        "How should central venous pressure be interpreted in sepsis?",
        "What biomarkers indicate adequate tissue perfusion?",
        "How do you assess fluid responsiveness in shock patients?",
        "What are the indications for invasive hemodynamic monitoring?"
      ]
    },
    {
      "category": "drug_dosing_protocols",
      "questions": [
        "How should vasopressors be weaned in recovering patients?",
        "What are the dose-response relationships for norepinephrine?",
        "How does sepsis alter drug clearance and distribution?",
        "What are the pharmacokinetic changes in renal dysfunction?",
        "How do you adjust dosing for hepatic impairment in ICU patients?"
      ]
    },
    {
      "category": "clinical_complications",
      "questions": [
        "How do you manage peripheral ischemia from vasopressors?",
        "What are the cardiac effects of high-dose catecholamines?",
        "How do you prevent extravasation injuries with vasopressors?",
        "What are the drug interactions with common ICU medications?",
        "How do you manage vasopressor-induced arrhythmias?"
      ]
    },
    {
      "category": "advanced_therapies",
      "questions": [
        "When should angiotensin II be considered in refractory shock?",
        "What are the indications for inotropic support vs vasopressors?",
        "How does ECMO affect drug pharmacokinetics?",
        "What is the role of corticosteroids in vasopressor-dependent shock?",
        "How do you approach catecholamine-resistant shock?"
      ]
    }
  ],
  "default_suggestions": [
    "What are the pharmacokinetic parameters of vasopressors in septic shock?",
    "How do alpha-adrenergic agonists affect systemic vascular resistance?",
    "What are the monitoring parameters for norepinephrine therapy?",
    "How does vasopressin differ from catecholamine vasopressors?",
    "What are the contraindications for high-dose epinephrine?",
    "What are the hemodynamic targets in distributive shock?",
    "How should vasopressors be weaned in recovering patients?",
    "How does sepsis alter drug clearance and distribution?",
    "How do you manage peripheral ischemia from vasopressors?",
    "When should angiotensin II be considered in refractory shock?"
  ]
}
